Objective      To explore the efficacy and safety of tacrolimus (TAC) and mycophenolate mofetil (MMF) in the treatment of type Ⅲ~Ⅴ Henoch-Schonlein purpura nephritis (HSPN).       Methods      A retrospective comparison trial of 58 type Ⅲ~Ⅴ HSPN patients in our hospital from January 2012 to November 2015 was performed. According to the types of special immunosuppressants

these patients were divided into TAC group (n=30) which was treated with oral TAC 0.05~0.1 mg/(kg·d)

and MMF group (n=28) which was treated with oral MMF 0.75~1.0 g/d. Both groups received the full-dose prednisone. The remission rate

average remission time

proteinuria

serum albumin and red blood cell count of urine microscopy were taken as the efficacy variables

while the incidence of adverse reactions was taken as the safety indicator.       Results      General information of the 2 groups

including clinical and pathological characteristics at baseline

had no statistical difference before treatment (P0.05). After treatment

proteinuria and red blood cell count of urinary sediment under microscopic examination decreased significantly in both groups

and serum albumin increased significantly (P0.05). However

the degree of variation had no statistical difference between the 2 groups (P0.05). Serum creatinine

estimated glomerular filtration rate (eGFR)

remission rate and average remission time were not statistically significant before and after treatment in both groups (P0.05). Adverse reactions between the TAC group (mainly hyperglycemia

tremors

alopecia

etc) and the MMF group (mainly increased cough

insomnia

hypercholesterolemia

etc) were significantly different (7/30 vs 14/28

23.3% vs 50.0%

P0.05).       Conclusion      TAC is non-inferior to MMF for therapy of HSPN and has lower adverse reactions.